Contents
Out of all the medical artificial intelligence promises made over time, a single instance has crossed the entire finish line: a randomized trial, a prespecified primary endpoint, and a published outcome. Focus on breast cancer screening, specifically through the MASAI trial. Spanning 105,934 women randomly assigned across the national screening initiative in Sweden, artificial intelligence-assisted analysis uncovered 29% more malignancies compared to traditional double interpretation—all while keeping false positives steady and slashing reading burdens by 44%. Furthermore, 2026 brought forward the previously missing metric: interval cancers, which serves as the definitive benchmark for evaluating whether a screening protocol remains safe. This piece breaks down the significance of this milestone and highlights what makes it truly unique.
The 30-second summary: the seven figures that matter
Each row names the study and the year. Note that the first three are successive publications from the same trial.
| Finding | Result | Study and year |
|---|---|---|
| Cancers detected per 1,000 women screened | 6.4 against 5.0; ratio of 1.29 (95% CI: 1.09-1.51; p = 0.0021) | Hernström et al., Lancet Digital Health (2025) |
| False positives | No increase: ratio of 1.01 (95% CI: 0.91-1.11; p = 0.92) | Hernström et al., Lancet Digital Health (2025) |
| Radiologist reading workload | 44.2% fewer reads | Hernström et al., Lancet Digital Health (2025) |
| Interval cancers, the primary endpoint | 1.55 against 1.76 per 1,000; ratio of 0.88, non-inferior | Gommers et al., The Lancet (2026) |
| Screening sensitivity | 80.5% against 73.8% (p = 0.031), at the same specificity | Gommers et al., The Lancet (2026) |
| Real-world rollout in Germany, 463,094 women | 6.7 against 5.7 per 1,000: 17.6% more detection | Eisemann et al., Nature Medicine (2025) |
| Reading reduction across 31 reviewed studies | Between 40% and 90% with triage strategies | Jassim et al., BMJ Open (2025) |
What you will find here
• How MASAI is designed and why its design differs from the rest.
• What an interval cancer is and why it was the missing figure.
- What transpired when it was administered to 463,094 women beyond the scope of a clinical trial.
- What the systematic review says is still unresolved.
The trial: how it was done
MASAI ran within Sweden’s national screening programme, at four centres in the south-west of the country. Between April 2021 and December 2022, 105,934 women were randomly assigned 1:1 to AI-supported screening or to standard double reading without AI. Median age was 53.7. Allocation was made automatically by the image archiving system after acquisition, and the radiologists doing the reading did not know which group each case belonged to.
The tool is used in two ways, and it is worth distinguishing them because that is where the result comes from. The system assigns each examination a risk score on a ten-level scale, used to decide whether that examination goes through one reading or two; and it also marks suspicious findings for the reading radiologist. At no point does it replace anyone: it reorganises the work and it points.
The detection results, published in Lancet Digital Health in 2025: 6.4 cancers per 1,000 women screened in the AI group against 5.0 in the control group, a ratio of 1.29 (95% CI: 1.09-1.51; p = 0.0021).
What other types of cancer were identified
This question is what separates a useful screening programme from one that merely generates diagnoses. The extra detection largely involved small invasive tumours lacking nodal involvement: 58 additional T1 cancers, 46 more without lymph-node spread, and 21 more belonging to non-luminal A subtypes. In situ carcinomas also rose, with roughly half of that surge being high grade.
And what did not happen: neither the recall rate nor the false-positive rate rose significantly, while the positive predictive value of recall improved with a ratio of 1.19 (95% CI: 1.04-1.37; p = 0.012). Reading workload fell from 109,692 to 61,248 reads: 44.2% fewer.
| Study | What it contributed | Result | What it cannot support |
|---|---|---|---|
| Lång et al., Lancet Oncology (2023) | Safety analysis with the first 80,033 women | Similar or higher detection; 44.3% fewer reads | An interim safety analysis, not the final endpoint |
| Hernström et al., Lancet Digital Health (2025) | Secondary outcomes with the full sample | 29% more detection without more false positives | Detection is not the same as patient benefit |
| Gommers et al., The Lancet (2026) | Primary endpoint: interval cancer | Non-inferior, with higher sensitivity and equal specificity | It does not measure mortality; follow-up is two years |
| Eisemann et al., Nature Medicine (2025) | Real-world rollout at 12 German centres | 17.6% more detection without worsening recall | Radiologists voluntarily chose whether to use the tool |
| Jassim et al., BMJ Open (2025) | Review of 31 studies and over 2 million examinations | Reading reduction of 40% to 90% with triage | Interval-cancer follow-up incomplete in several datasets |
The missing figure: interval cancers
Identifying a higher volume of cancers doesn’t automatically prove the superiority of a screening initiative. An initiative can boost its detection stats by spotting growths that would have otherwise remained harmless, all while failing to catch the fast-moving ones. The metric designed to capture this flaw is the interval cancer: precisely the one surfacing in the gap between successive screening sessions, meaning the one the process failed to spot.
That was MASAI’s primary endpoint, published in The Lancet in 2026, with a prespecified non-inferiority margin of 20%.
| Metric | With AI | Standard double reading |
|---|---|---|
| Interval cancers per 1,000 participants | 1.55 (95% CI: 1.23-1.92) | 1.76 (95% CI: 1.42-2.15) |
| Proportion ratio | 0.88 (95% CI: 0.65-1.18) | p = 0.41: non-inferior |
| Invasive interval cancers | 75 | 89 |
| Interval cancers at stage T2 or above | 38 | 48 |
| Sensitivity | 80.5% (76.4-84.2) | 73.8% (68.9-78.3); p = 0.031 |
| Specificity | 98.5% | 98.5%; p = 0.88 |
The result meets the requirement and adds something more. Not only were there no additional interval cancers, but those that did occur in the AI group tended to be less invasive and at a lower stage, and programme sensitivity rose by nearly seven points without losing a tenth of a point of specificity. It is a clean result, and a rare one in this field.
What occurs beyond the trial
A clinical trial provides a controlled setting. Subsequently, whether this holds true within an actual programme remains to be seen, and a substantial reply is available. The PRAIM study, published in Nature Medicine in 2025, followed 463,094 women aged 50 to 69 screened at 12 German centres between July 2021 and February 2023, read by 119 radiologists.
The detection rate in the AI-supported group was 6.7 per 1,000 against 5.7 in the control group: 17.6% more (95% CI: 5.7% to 30.8%), statistically superior. The recall rate was slightly lower and non-inferior, and the positive predictive value rose from 14.9% to 17.9%.
There is one limitation the authors themselves flag and that should not be glossed over: radiologists voluntarily chose whether to use the system, so this is not random assignment and there could be differences between those who used it and those who did not.
What the systematic review qualifies
The most extensive synthesis currently accessible was brought to light by Ghufran Jassim and co-authors in BMJ Open in 2025: 31 studies covering more than two million screening examinations across Europe, Asia, North America and Australia.
Their conclusions align with the points above on the core aspects. Serving as a second reader or embedded in double-reading processes, artificial intelligence sustains or slightly boosts sensitivity—by as much as nine percentage points—while maintaining or enhancing specificity; additionally, triage setups cut reading volume by 40% to 90% while keeping detection non-inferior when thresholds are set conservatively.
But they add two reservations. The first concerns overall certainty: heterogeneity across designs and the use of enriched datasets limit some accuracy estimates, and interval-cancer follow-up is incomplete in several major studies. The second concerns autonomous use: transparent reporting, standardised evaluation and long-term population studies are needed before considering AI as a stand-alone reader.
Practical applications for this
Ordered by the strength of the evidence behind it:
• Always ask for the interval-cancer figure. It represents the critical metric that distinguishes finding more from finding better, and the exact data MASAI delayed publishing for three years.
• The part illustrated here involves triage and support rather than acting as the sole reader. That approach is what the clinical trial assessed and what the systematic review currently deems safe.
- Examine the supplementary type of tumour identified. Within MASAI, compact invasive malignancies lacking lymph node involvement predominated, perfectly fulfilling the core objective of screening.
- Verify that the recall does not increase. The worth of the outcome stems from spotting more instances without incurring a penalty in false positives.
• Distinguish trial from rollout. The German study of 463,094 women is large, but use of the tool was voluntary and that is not random assignment.
Frequently asked questions
Does artificial intelligence detect more breast cancers than radiologists?
In supported screening, yes, and it is measured in a randomised trial. In MASAI, with 105,934 women from Sweden’s national programme, detection was 6.4 cancers per 1,000 screened with AI against 5.0 with standard double reading, a ratio of 1.29 (95% CI: 1.09-1.51; p = 0.0021). The AI was not reading alone: it sorted examinations and marked findings for the radiologist.
Do false positives increase?
Not significantly. Within that very same trial, the false-positive ratio stood at 1.01 (95% CI: 0.91-1.11; p = 0.92) alongside a recall ratio of 1.08 (0.99-1.17; p = 0.084), whereas the positive predictive value concerning recall saw an enhancement with a ratio reaching 1.19 (p = 0.012).
What is an interval cancer and why does it matter so much?
It represents the malignancy developing between consecutive screening intervals, specifically the one missed by the initial examination. Serving as the core objective for MASAI, the findings shared in The Lancet in 2026 indicated 1.55 cases per 1,000 using artificial intelligence compared to 1.76 without it, yielding a proportion of 0.88 (95% CI: 0.65-1.18) that successfully satisfied the non-inferiority benchmark. Absent this metric, merely identifying a higher volume of tumors fails to demonstrate superior screening efficacy.
How much work does it save?
Around half the reads. MASAI achieved 61,248 reads within the AI cohort compared to 109,692 in the control cohort, representing a 44.2% decrease, whereas the analysis of 31 studies estimates this drop to fall between 40% and 90%, depending on the specific triage approach implemented.
Is it possible for artificial intelligence to independently read mammograms?
Not yet, on the available evidence. The systematic review published in BMJ Open in 2025 concludes that transparent reporting, standardised evaluation and long-term population studies are needed before considering AI as a stand-alone reader, and notes that interval-cancer follow-up is incomplete in several of the available datasets.
What we do not know
• Whether it reduces mortality. No study has measured it: the hardest endpoint available so far is interval cancer at two years.
• What happens across several screening rounds. The published follow-up covers one interval, not a lifetime of successive screens.
- Whether the outcome relies on the specific setup. MASAI utilized a distinct release of a commercial software, and comparative, randomised evaluations between platforms are absent.
• How it behaves in different populations. The large studies are Swedish, Danish and German, with organised screening programmes and relatively homogeneous populations.
References
1. Hernström, V., Josefsson, V. et al. Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI). The Lancet Digital Health, 2025. DOI: 10.1016/s2589-7500(24)00267-x
2. Gommers, J., Hernström, V. et al. Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study. The Lancet, 2026. DOI: 10.1016/s0140-6736(25)02464-x
3. Lång, K., Josefsson, V. et al. Artificial intelligence-supported screen reading versus standard double reading in the MASAI trial: a clinical safety analysis. The Lancet Oncology, 2023. DOI: 10.1016/s1470-2045(23)00298-x
4. Eisemann, N., Bunk, S. et al. Nationwide real-world implementation of AI for cancer detection in population-based mammography screening. Nature Medicine, 2025. DOI: 10.1038/s41591-024-03408-6
5. Jassim, G., Otoom, O. et al. Performance of artificial intelligence in breast cancer screening programmes: a systematic review. BMJ Open, 2025. DOI: 10.1136/bmjopen-2025-111360
This material is purely informational and should not be considered medical guidance. The outcomes detailed originate from structured screening initiatives employing dedicated systems and protocols, meaning they cannot be applied directly to alternative clinical environments or personal choices regarding diagnostic procedures.